Patient Derived Xenograft Model Market
PUBLISHED: 2025 ID: SMRC28372
SHARE
SHARE

Patient Derived Xenograft Model Market

Patient-derived Xenograft Model Market Forecasts to 2030 - Global Analysis By Model Type (Mice Models and Rat Models), Tumor Type (Gastrointestinal Tumors, Gynecological Tumors, Respiratory Tumors and Other Tumor Types), Implantation Method (Subcutaneous and Orthotopic), Application, End User and By Geography

4.2 (33 reviews)
4.2 (33 reviews)
Published: 2025 ID: SMRC28372

This report covers the impact of COVID-19 on this global market
Loading...

Years Covered

2022-2030

Estimated Year Value (2024)

US $494.3 MN

Projected Year Value (2030)

US $1102.3 MN

CAGR (2024-2030)

14.3%

Regions Covered

North America, Europe, Asia Pacific, South America, and Middle East & Africa

Countries Covered

US, Canada, Mexico, Germany, UK, Italy, France, Spain, Japan, China, India, Australia, New Zealand, South Korea, Rest of Asia Pacific, South America, Argentina, Brazil, Chile, Middle East & Africa, Saudi Arabia, UAE, Qatar, and South Africa

Largest Market

North America

Highest Growing Market

Asia Pacific


According to Stratistics MRC, the Global Patient-derived Xenograft Model Market is accounted for $494.3 million in 2024 and is expected to reach $1102.3 million by 2030 growing at a CAGR of 14.3% during the forecast period. An experimental system known as a patient-derived xenograft (PDX) model involves implanting tumor tissues from human patients into immunocompromised mice. This model is a useful tool for cancer research because it maintains the original tumor's genetic and phenotypic features. Compared to conventional cell line models, PDX models provide a more realistic depiction of human cancer and are utilized to investigate tumor biology, test therapeutic medications, and create personalized medicine strategies.

According to Dana-Farber Cancer Institute study, 16 out of 29 patients with advanced sarcoma successfully established PDX models.

Market Dynamics:

Driver: 

Rising demand for personalized medicine

The rising demand for personalized medicine is driving the patient-derived xenograft (PDX) model market. PDX models enable researchers to study patient-specific cancer biology and drug responses, making them essential for tailoring treatments to individual genetic profiles. This approach improves therapeutic efficacy and reduces adverse effects, aligning with the growing focus on precision oncology. The increasing prevalence of cancer and advancements in genomics further amplify the need for personalized medicine.

Restraint:

High costs of development and maintenance

Establishing and sustaining PDX models require significant financial resources, specialized expertise, and advanced infrastructure. The complex processes involved in tumor implantation and maintenance limit accessibility for smaller research organizations. Additionally, the high cost of immunodeficient animals and human tumor samples further increases expenses. These financial barriers pose challenges to widespread adoption.

Opportunity:

Advancements in cancer research

Advancements in cancer research are creating opportunities for the PDX model market. Innovations such as CRISPR-based gene editing, AI-driven data analysis and humanized PDX models are enhancing the accuracy and efficiency of preclinical studies. These advancements allow researchers to explore novel therapeutic targets, improve biomarker discovery, and accelerate drug development processes. Additionally, increasing public and private investments in oncology research are driving demand for advanced PDX models.

Threat:

Ethical concerns and regulatory challenges

Ethical concerns and regulatory challenges threaten the growth of the PDX model market. The use of animals in research raises ethical issues, leading to stringent guidelines that can delay or restrict studies. Regulatory agencies like the FDA have introduced measures to reduce reliance on animal models, potentially affecting market dynamics. These challenges necessitate compliance with complex protocols, increasing operational costs and timeframes for research organizations.

Covid-19 Impact: 

The COVID-19 pandemic negatively impacted the PDX model market due to disruptions in laboratory operations, supply chains, and research funding. Many oncology studies were delayed as resources were diverted toward COVID-19 research. However, the pandemic underscored the importance of personalized medicine, highlighting the relevance of PDX models in cancer research. As restrictions eased, demand rebounded with renewed focus on innovative cancer therapies.

The mice models segment is expected to be the largest during the forecast period

The mice models segment is expected to account for the largest market share during the forecast period. Mice are widely used due to their genetic similarity to humans, ease of handling, and cost-effectiveness compared to other animals. They provide a robust platform for studying tumor growth, drug efficacy, and resistance mechanisms in vivo. The availability of well-established protocols for mice-based PDX models further supports their dominance in preclinical oncology research.

The biobanking segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the biobanking segment is expected to witness the highest CAGR due to its role in preserving patient-derived tumor samples for future use. Biobanks enable researchers to access diverse tumor specimens for developing new PDX models and conducting retrospective studies. This capability accelerates drug discovery processes while ensuring reproducibility in experiments. The growing emphasis on personalized medicine drives demand for biobanking services as an essential component of preclinical research infrastructure.

Region with largest share:

The North America region is anticipated to account for the largest market share during the forecast period. Factors such as a high prevalence of cancer, advanced healthcare infrastructure, and significant public-private investments in oncology research drive regional growth. The presence of key industry players further strengthens North America's position as a leader in PDX model adoption. Additionally, government initiatives supporting precision medicine also contribute significantly to this dominance.

Region with highest CAGR:

The Asia Pacific region is anticipated to register the highest growth rate over the forecast period. Rapid urbanization, increasing healthcare expenditure, and rising cancer incidence drive demand for advanced research tools like PDX models in this region. The shift toward modern healthcare practices positions Asia Pacific as a key growth hub. Furthermore, countries like China and India are investing heavily in biotechnology and pharmaceutical R&D, fostering market expansion.

Key players in the market

Some of the key players in Patient-derived Xenograft Model Market include Champions Oncology, Charles River Laboratories, Crown Bioscience, EPO Berlin-Buch, Hera BioLabs, Horizon Discovery Group, Inotiv, JSR Corporation, Oncodesign Precision Medicine, Pharmatest Services, Taconic Biosciences, The Jackson Laboratory, Urolead, WuXi AppTec, Xenopat and Xentech.

Key Developments:

In December 2024, Can-Fite BioPharma Ltd. recently announced that its work titled The Liver Protective Effect of the Anti-Cancer Drug Candidate Namodenoson is mediated via Adiponectin will be presented at the 2025 ASCO Gastrointestinal Cancers Symposium to take place at San Francisco & On Line, January 23-25.

In October 2019, Crown Bioscience announced the launch of a new tumor organoid drug development platform with the potential to significantly improve the predictivity and speed of preclinical drug discovery. The initial phase of the platform launch features the first commercially available 3D in vitro PDX-derived organoid (PDXO) models generated from CrownBio’s uniquely-characterized library of 2500+ patient-derived xenograft (PDX) models.

In May 2015, Taconic Biosciences and Cellaria Biosciences have entered into a scientific collaboration designed to improve the utility of patient-derived xenografts (PDXs) in animal models for oncology and immuno-oncology research. Cellaria’s novel methodologies for generating cells from patient tumors will complement Taconic’s industry-leading portfolio of tissue humanized mouse models, which are said to be well suited as hosts for PDXs.

Model Types Covered:
• Mice Models
• Rat Models

Tumor Types Covered:
• Gastrointestinal Tumors
• Gynecological Tumors
• Respiratory Tumors
• Breast Cancer Tumors
• Hematological Tumors
• Urological Tumors
• Neurological Tumors
• Other Tumor Types

Implantation Methods Covered:
• Subcutaneous
• Orthotopic

Applications Covered:
• Preclinical Drug Development
• Biomarker Analysis
• Biobanking
• Translational Research

End Users Covered:
• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutions
• Contract Research Organizations

Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan        
o China        
o India        
o Australia  
o New Zealand
o South Korea
o Rest of Asia Pacific    
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa 
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings: 
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary       
        
2 Preface  
    
 2.1 Abstract      
 2.2 Stake Holders      
 2.3 Research Scope      
 2.4 Research Methodology      
  2.4.1 Data Mining     
  2.4.2 Data Analysis     
  2.4.3 Data Validation     
  2.4.4 Research Approach     
 2.5 Research Sources      
  2.5.1 Primary Research Sources     
  2.5.2 Secondary Research Sources     
  2.5.3 Assumptions     
        
3 Market Trend Analysis       
 3.1 Introduction      
 3.2 Drivers      
 3.3 Restraints      
 3.4 Opportunities      
 3.5 Threats      
 3.6 Application Analysis      
 3.7 End User Analysis      
 3.8 Emerging Markets      
 3.9 Impact of Covid-19      
        
4 Porters Five Force Analysis       

 4.1 Bargaining power of suppliers      
 4.2 Bargaining power of buyers      
 4.3 Threat of substitutes      
 4.4 Threat of new entrants      
 4.5 Competitive rivalry      
        
5 Global Patient-derived Xenograft Model Market, By Model Type       
 5.1 Introduction      
 5.2 Mice Models      
  5.2.1 NOD SCID Models     
  5.2.2 NSG Models     
  5.2.3 Other Immunodeficient Models     
 5.3 Rat Models      
  5.3.1 Immunodeficient Rat Models     
  5.3.2 Humanized Rat Models     
        
6 Global Patient-derived Xenograft Model Market, By Tumor Type        
 6.1 Introduction      
 6.2 Gastrointestinal Tumors      
 6.3 Gynecological Tumors      
 6.4 Respiratory Tumors      
 6.5 Breast Cancer Tumors      
 6.6 Hematological Tumors      
 6.7 Urological Tumors      
 6.8 Neurological Tumors      
 6.9 Other Tumor Types      
        
7 Global Patient-derived Xenograft Model Market, By Implantation Method       
 7.1 Introduction      
 7.2 Subcutaneous      
 7.3 Orthotopic      
  7.3.1 Surgical Implantation     
  7.3.2 Non-surgical Implantation     
        
8 Global Patient-derived Xenograft Model Market, By Application       
 8.1 Introduction      
 8.2 Preclinical Drug Development      
 8.3 Biomarker Analysis      
 8.4 Biobanking      
 8.5 Translational Research      
        
9 Global Patient-derived Xenograft Model Market, By End User       
 9.1 Introduction      
 9.2 Pharmaceutical & Biotechnology Companies      
 9.3 Academic & Research Institutions      
 9.4 Contract Research Organizations      
        
10 Global Patient-derived Xenograft Model Market, By Geography       
 10.1 Introduction      
 10.2 North America      
  10.2.1 US     
  10.2.2 Canada     
  10.2.3 Mexico     
 10.3 Europe      
  10.3.1 Germany     
  10.3.2 UK     
  10.3.3 Italy     
  10.3.4 France     
  10.3.5 Spain     
  10.3.6 Rest of Europe     
 10.4 Asia Pacific      
  10.4.1 Japan     
  10.4.2 China     
  10.4.3 India     
  10.4.4 Australia     
  10.4.5 New Zealand     
  10.4.6 South Korea     
  10.4.7 Rest of Asia Pacific     
 10.5 South America      
  10.5.1 Argentina     
  10.5.2 Brazil     
  10.5.3 Chile     
  10.5.4 Rest of South America     
 10.6 Middle East & Africa      
  10.6.1 Saudi Arabia     
  10.6.2 UAE     
  10.6.3 Qatar     
  10.6.4 South Africa     
  10.6.5 Rest of Middle East & Africa     
        
11 Key Developments       
 11.1 Agreements, Partnerships, Collaborations and Joint Ventures      
 11.2 Acquisitions & Mergers      
 11.3 New Product Launch      
 11.4 Expansions      
 11.5 Other Key Strategies      
        
12 Company Profiling       
 12.1 Champions Oncology      
 12.2 Charles River Laboratories      
 12.3 Crown Bioscience      
 12.4 EPO Berlin-Buch      
 12.5 Hera BioLabs      
 12.6 Horizon Discovery Group      
 12.7 Inotiv      
 12.8 JSR Corporation      
 12.9 Oncodesign Precision Medicine      
 12.10 Pharmatest Services      
 12.11 Taconic Biosciences      
 12.12 The Jackson Laboratory      
 12.13 Urolead      
 12.14 WuXi AppTec      
 12.15 Xenopat      
 12.16 Xentech      
        
List of Tables        
1 Global Patient-derived Xenograft Model Market Outlook, By Region (2022-2030) ($MN)       
2 Global Patient-derived Xenograft Model Market Outlook, By Model Type (2022-2030) ($MN)       
3 Global Patient-derived Xenograft Model Market Outlook, By Mice Models (2022-2030) ($MN)       
4 Global Patient-derived Xenograft Model Market Outlook, By NOD SCID Models (2022-2030) ($MN)       
5 Global Patient-derived Xenograft Model Market Outlook, By NSG Models (2022-2030) ($MN)       
6 Global Patient-derived Xenograft Model Market Outlook, By Other Immunodeficient Models (2022-2030) ($MN)       
7 Global Patient-derived Xenograft Model Market Outlook, By Rat Models (2022-2030) ($MN)       
8 Global Patient-derived Xenograft Model Market Outlook, By Immunodeficient Rat Models (2022-2030) ($MN)       
9 Global Patient-derived Xenograft Model Market Outlook, By Humanized Rat Models (2022-2030) ($MN)       
10 Global Patient-derived Xenograft Model Market Outlook, By Tumor Type  (2022-2030) ($MN)       
11 Global Patient-derived Xenograft Model Market Outlook, By Gastrointestinal Tumors (2022-2030) ($MN)       
12 Global Patient-derived Xenograft Model Market Outlook, By Gynecological Tumors (2022-2030) ($MN)       
13 Global Patient-derived Xenograft Model Market Outlook, By Respiratory Tumors (2022-2030) ($MN)       
14 Global Patient-derived Xenograft Model Market Outlook, By Breast Cancer Tumors (2022-2030) ($MN)       
15 Global Patient-derived Xenograft Model Market Outlook, By Hematological Tumors (2022-2030) ($MN)       
16 Global Patient-derived Xenograft Model Market Outlook, By Urological Tumors (2022-2030) ($MN)       
17 Global Patient-derived Xenograft Model Market Outlook, By Neurological Tumors (2022-2030) ($MN)       
18 Global Patient-derived Xenograft Model Market Outlook, By Other Tumor Types (2022-2030) ($MN)       
19 Global Patient-derived Xenograft Model Market Outlook, By Implantation Method (2022-2030) ($MN)       
20 Global Patient-derived Xenograft Model Market Outlook, By Subcutaneous (2022-2030) ($MN)       
21 Global Patient-derived Xenograft Model Market Outlook, By Orthotopic (2022-2030) ($MN)       
22 ""Global Patient-derived Xenograft Model Market Outlook, By Surgical Implantation (2022-2030) ($MN)      
23 Global Patient-derived Xenograft Model Market Outlook, By Non-surgical Implantation (2022-2030) ($MN)       
24 Global Patient-derived Xenograft Model Market Outlook, By Application (2022-2030) ($MN)       
25 Global Patient-derived Xenograft Model Market Outlook, By Preclinical Drug Development (2022-2030) ($MN)       
26 Global Patient-derived Xenograft Model Market Outlook, By Biomarker Analysis (2022-2030) ($MN)       
27 Global Patient-derived Xenograft Model Market Outlook, By Biobanking (2022-2030) ($MN)       
28 Global Patient-derived Xenograft Model Market Outlook, By Translational Research (2022-2030) ($MN)       
29 Global Patient-derived Xenograft Model Market Outlook, By End User (2022-2030) ($MN)       
30 Global Patient-derived Xenograft Model Market Outlook, By Pharmaceutical & Biotechnology Companies (2022-2030) ($MN)       
31 Global Patient-derived Xenograft Model Market Outlook, By Academic & Research Institutions (2022-2030) ($MN)       
32 Global Patient-derived Xenograft Model Market Outlook, By Contract Research Organizations (2022-2030) ($MN)       
        
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.        

List of Figures

RESEARCH METHODOLOGY


Research Methodology

We at Stratistics opt for an extensive research approach which involves data mining, data validation, and data analysis. The various research sources include in-house repository, secondary research, competitor’s sources, social media research, client internal data, and primary research.

Our team of analysts prefers the most reliable and authenticated data sources in order to perform the comprehensive literature search. With access to most of the authenticated data bases our team highly considers the best mix of information through various sources to obtain extensive and accurate analysis.

Each report takes an average time of a month and a team of 4 industry analysts. The time may vary depending on the scope and data availability of the desired market report. The various parameters used in the market assessment are standardized in order to enhance the data accuracy.

Data Mining

The data is collected from several authenticated, reliable, paid and unpaid sources and is filtered depending on the scope & objective of the research. Our reports repository acts as an added advantage in this procedure. Data gathering from the raw material suppliers, distributors and the manufacturers is performed on a regular basis, this helps in the comprehensive understanding of the products value chain. Apart from the above mentioned sources the data is also collected from the industry consultants to ensure the objective of the study is in the right direction.

Market trends such as technological advancements, regulatory affairs, market dynamics (Drivers, Restraints, Opportunities and Challenges) are obtained from scientific journals, market related national & international associations and organizations.

Data Analysis

From the data that is collected depending on the scope & objective of the research the data is subjected for the analysis. The critical steps that we follow for the data analysis include:

  • Product Lifecycle Analysis
  • Competitor analysis
  • Risk analysis
  • Porters Analysis
  • PESTEL Analysis
  • SWOT Analysis

The data engineering is performed by the core industry experts considering both the Marketing Mix Modeling and the Demand Forecasting. The marketing mix modeling makes use of multiple-regression techniques to predict the optimal mix of marketing variables. Regression factor is based on a number of variables and how they relate to an outcome such as sales or profits.


Data Validation

The data validation is performed by the exhaustive primary research from the expert interviews. This includes telephonic interviews, focus groups, face to face interviews, and questionnaires to validate our research from all aspects. The industry experts we approach come from the leading firms, involved in the supply chain ranging from the suppliers, distributors to the manufacturers and consumers so as to ensure an unbiased analysis.

We are in touch with more than 15,000 industry experts with the right mix of consultants, CEO's, presidents, vice presidents, managers, experts from both supply side and demand side, executives and so on.

The data validation involves the primary research from the industry experts belonging to:

  • Leading Companies
  • Suppliers & Distributors
  • Manufacturers
  • Consumers
  • Industry/Strategic Consultants

Apart from the data validation the primary research also helps in performing the fill gap research, i.e. providing solutions for the unmet needs of the research which helps in enhancing the reports quality.


For more details about research methodology, kindly write to us at info@strategymrc.com

Frequently Asked Questions

In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929

Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.

Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.

All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929

We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.

We have 3 different licensing options available in electronic format.

  • Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
  • 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
  • Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.

All our reports are typically be emailed to you as an attachment.

To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.

We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.

Request Customization

We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.

Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.

WHY CHOOSE US ?

Assured Quality

Assured Quality

Best in class reports with high standard of research integrity

24X7 Research Support

24X7 Research Support

Continuous support to ensure the best customer experience.

Free Customization

Free Customization

Adding more values to your product of interest.

Safe and Secure Access

Safe & Secure Access

Providing a secured environment for all online transactions.

Trusted by 600+ Brands

Trusted by 600+ Brands

Serving the most reputed brands across the world.

Testimonials